DESCRIPTION
Pomalid (pomalidomide) 1mg is a Natco pharma product which is endorsed by FDA, containing an active anti-cancer drug called pomalidomide. Pomalid(pomalyst) 1mg is available as orally bioavailable thalidomide derivative with various therapeutic activities such as; Immuno modulatory Anti-angiogenesis Anti-neoplastic Pomalid(pomalidomide) 1mg is similar to thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment. This may leads to severe liver injury. Pomalid is involved in the treatment for regression & unmanageable multiple myeloma. Pomalid( is used in the patients who are failing to response for Lenalidomide treatment. Pomalid(pomalyst) 1mg is used in combination with dexamethasone.
INDICATION
The major therapeutic indication of Pomalid 1mg ,2mg,4mg is involved in the treatment of multiple myeloma.
This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomalid 1mg ,2mg,4mg
Pomalid(pomalidomide) is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor.
This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomalid 1mg ,2mg,4mg
Pomalid(pomalidomide) is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor.
DOSAGE & ADMINISTRATION
During hematological toxicities;
Neutropenia :
ANC (absolute neutrophils count) <500/mcl: Postpone the Pomalid therapy and provide CBC weekly ANC more than or equal to 500/mcl: Continue the Pomalid 3mg daily.
Thrombocytopenia :
Platelets count <25,000/mcL: postpone the Pomalid treatment & follow the CBC >50,000/mcL: continue 3mg of Pomalid
Pomalid 1mg ,2mg,4mg with potent CYP1A2 inhibitor :
During this combination reduce the dose of Pomalid by 50%
In renal impairment :
Initial dose of Pomalid(pomalidomide) is 3mg
In hepatic impairment :
Mild to moderate condition, an initial dose of Pomalid(pomalyst) is 3mg; in severe condition, the initial dose of Pomalid(pomalidomide) is 2mg.
Neutropenia :
ANC (absolute neutrophils count) <500/mcl: Postpone the Pomalid therapy and provide CBC weekly ANC more than or equal to 500/mcl: Continue the Pomalid 3mg daily.
Thrombocytopenia :
Platelets count <25,000/mcL: postpone the Pomalid treatment & follow the CBC >50,000/mcL: continue 3mg of Pomalid
Pomalid 1mg ,2mg,4mg with potent CYP1A2 inhibitor :
During this combination reduce the dose of Pomalid by 50%
In renal impairment :
Initial dose of Pomalid(pomalidomide) is 3mg
In hepatic impairment :
Mild to moderate condition, an initial dose of Pomalid(pomalyst) is 3mg; in severe condition, the initial dose of Pomalid(pomalidomide) is 2mg.
POMALID 1MG WORKS
Pomalid(pomalyst) 1mg exhibits various activities like;
Anti-neoplastic activity
Prohibits proliferation Promote apoptosis of hematopoietic cancer cells Co adjuvant with dexamethasone in both Lenalidomide sensitive & resistant myeloma cells to activate the tumor cell apoptosis
Immuno modulatory
Boosted the T-cells & natural killer cell mediate immunity. The drug is prohibited the formation of pro-inflammatory cytokines by monocytes.
Anti-angiogenesis
Interfere with formation of new vessels and leads to inhibit the cell division.
WARNING
There are two major worsening condition may occur during the treatment using with Pomalid 1mg ,2mg,4mg.
Embryo fetal damage
Pomalid 1mg ,2mg,4mg capsules are contraindicated to pregnancy period. During the treatment, patients avoid to becoming pregnant. Use effective contraceptives for preventing pregnancy during therapy.
Venous & arterial thromboembolism
Patient who are receiving Pomalid 1mg ,2mg,4mg capsules have chance of getting deep vein thrombosis, pulmonary embolism, myocardial infarction & stroke. This type of condition should be treated by initiating prophylactic anti-thrombotic drugs. The patients who are acquiring this condition then thromboprophylaxis should be provided
DRUG INTERACTION
Pomalid 1mg ,2mg,4mg metabolism is mediated by CYP1A2 & CYP3A4. The concomitant use of Pomalid 1mg ,2mg,4mg with CYP1A2 drugs like Fluoxamine causes elevation of Cmax & AUC of Pomalidomide and concludes as increased concentration of Pomalid leads to higher extent of adverse effects associated with Pomalid In this condition, reduce the dose of Pomalid 1mg ,2mg,4mg and recommended.
For more Information
Call us : +91–9987711567
Mail to : applepharmaceutical@gmail.com
